Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7830698 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Part 1: Single Ascending Dose (SAD) | EXPERIMENTAL | Healthy participants will receive single doses of RO7830698 or placebo. |
| Part 2: Multiple Ascending Dose (MAD) | EXPERIMENTAL | Participants with COPD will receive multiple doses of RO7830698 or placebo. |
| Name | Type | Description |
|---|---|---|
| RO7830698 | DRUG | Participants will receive RO7830698 as per the schedule described in the protocol. |
| Placebo | DRUG | Participants will receive placebo as per the schedule described in the protocol. |
Inclusion Criteria: All participants: * Body mass index (BMI) between 18 and 32 kilograms per meter square (kg/m2) * Agreement to adhere to the contraception requirements Part 1: * Absence of evidence of any active or chronic disease Part 2: * Confirmed diagnosis of COPD for \> 6 months, as de...
RO7830698 is an investigational small molecule being developed by Roche Holding AG for chronic obstructive pulmonary disease (COPD). It is in Phase 1 clinical development and is being studied in a single recruiting trial that enrolls both healthy participants and participants with COPD.
RO7830698 is being developed as a treatment for chronic obstructive pulmonary disease (COPD), a respiratory condition. It is investigational and has not been established as a therapy; the current Phase 1 study evaluates it in participants with COPD alongside healthy participants in the United Kingdom.
RO7830698 is being developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is the sponsor of the Phase 1 study of the compound in healthy participants and participants with COPD.
RO7830698 is in Phase 1 clinical development. It is investigational and is not approved for any use. One Phase 1 trial is currently recruiting, and no trials of RO7830698 have been completed.
RO7830698 is being studied in trial NCT07822334, titled A Study of RO7830698 in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease. The Phase 1 trial is recruiting, is randomized, double-blind, and controlled, plans to enroll 104 participants, and is conducted in the United Kingdom.